Answers are grounded in this paper and cite their sources.
PANoptosis is a novel form of programmed cell death driven by the PANoptosome complex, which integrates key features of apoptosis, pyroptosis, and necroptosis. Existing pre-clinical research indicates that PANoptosis participates in tissue injury processes in ischemic diseases, including cerebral, myocardial, renal, retinal, and lower limb ischemia. Intervening in its core regulators reduces injury in animal models. A defining characteristic of PANoptosis is its intricate interplay with other cell death pathways, primarily mediated by shared molecular hubs such as CASP8, RIPK1, and ZBP1, which form a dynamic regulatory network. This mechanism provides new pathological dimensions for understanding ischemic injury and offers directions for exploring novel therapeutic strategies. Specifically, targeting the intersection points between PANoptosis and other death pathways enables the coordinated inhibition of multiple cell death routes, potentially overcoming the limitations of traditional single-target therapies. This review systematically summarizes the regulatory network of PANoptosis in ischemic diseases and highlights current therapeutic strategies and recent advances focused on key nodes, including upstream mitochondrial stress, PANoptosome assembly, and downstream effector molecules. Meanwhile, the limitations of current evidence and the challenges for future translation are discussed, aiming to provide theoretical references for future interventions in ischemic diseases.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: